



PATENT APPLICATION
File No: 00-25

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Darrell C. Conklin, Zeren Gao
Serial No. : 09/819,136
Group Art Unit : 1652
Examiner : Ramirez, D.
Filed : March 27, 2001
For : MULTI-DOMAIN PROTEINASE INHIBITOR
Date Submitted : December 14, 2001

RECEIVED

JAN 30 2002

TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.
The fee required to be filed with the accompanying amendment has been calculated as shown below:


CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	11	-25		\$9.00	\$000.00
Independent	4	-5		\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
Total					\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker
Registration No. 31,648



1652

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231.

Dec. 14, 2001

Date

Gary E. Parker

7/a
S. G. J
2/4/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants : Darrell C. Conklin, Zeren Gao
Serial No. : 09/819,136
Filed : March 27, 2001
For : MULTI-DOMAIN PROTEINASE INHIBITOR

JAN 30 2002

TECH CENTER 1600/2900

Examiner : Ramirez, D.
Art Unit : 1652
Docket No. : 00-25
Date : December 14, 2001

BOX NON-FEE AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement and Preliminary Amendment

Sir:

Please amend the above-identified application as follows:

In the Claims:

Please cancel claims 9-22 and 25 without prejudice.

Please replace claims 23 and 24 with the following amended claims:

23. (amended) A protein produced by a method comprising the steps

of:

(a) culturing a cell comprising an expression vector comprising the

following operably linked elements:

a transcription promoter;

A1
Rev C12